These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35713182)

  • 41. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
    Tang H; Zhou L; Li X; Kinlaw AC; Yang JY; Moon AM; Barnes EL; Wang T
    Int J Clin Pharm; 2021 Aug; 43(4):1116-1122. PubMed ID: 34328585
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
    Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
    Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
    Nicholls C; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of gynecomastia with antidiabetic medications in older adults: Data mining from different national pharmacovigilance databases.
    Ohyama K; Tanaka H; Shindo J; Shibayama M; Iwata M; Hori Y
    Int J Clin Pharmacol Ther; 2022 Jan; 60(1):24-31. PubMed ID: 34622771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between nocturnal falls and hypnotic drug use in older patients at acute care hospitals.
    Oda S; Takechi K; Hirai S; Takatori S; Otsuka T
    Eur J Clin Pharmacol; 2023 Jun; 79(6):753-758. PubMed ID: 37010536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.
    Gaimari A; Fusaroli M; Raschi E; Baldin E; Vignatelli L; Nonino F; De Ponti F; Mandrioli J; Poluzzi E
    Drug Saf; 2022 Jun; 45(6):663-673. PubMed ID: 35610460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
    Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
    Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Fahim SM; Mishuk AU; Cheng N; Hansen R; Calderón AI; Qian J
    Expert Opin Drug Saf; 2019 Feb; 18(2):145-152. PubMed ID: 30576263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.
    Antonazzo IC; Raschi E; Forcesi E; Riise T; Bjornevik K; Baldin E; De Ponti F; Poluzzi E
    Expert Opin Drug Saf; 2018 Sep; 17(9):869-874. PubMed ID: 30058390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spontaneous Adverse Event Reports Associated with Zolpidem in the United States 2003-2012.
    Wong CK; Marshall NS; Grunstein RR; Ho SS; Fois RA; Hibbs DE; Hanrahan JR; Saini B
    J Clin Sleep Med; 2017 Feb; 13(2):223-234. PubMed ID: 27784418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
    Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians.
    Wilt TJ; MacDonald R; Brasure M; Olson CM; Carlyle M; Fuchs E; Khawaja IS; Diem S; Koffel E; Ouellette J; Butler M; Kane RL
    Ann Intern Med; 2016 Jul; 165(2):103-12. PubMed ID: 27136278
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
    Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
    J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study.
    Guan Y; Qi Y; Zheng L; Yang J; Zhang M; Zhang Q; Ji L
    BMJ Open; 2023 Jan; 13(1):e068127. PubMed ID: 36669842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
    Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
    Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
    Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
    Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system.
    Chinzowu T; Chyou TY; Nishtala PS
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1190-1198. PubMed ID: 35670078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
    Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
    Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database.
    Nair HP; Kulkarni AR; Eswaran M; Subeesh V
    Arab J Gastroenterol; 2023 Feb; 24(1):1-4. PubMed ID: 36725376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database.
    Kazerooni R; Armstrong EP
    Clin Drug Investig; 2018 Sep; 38(9):867-872. PubMed ID: 29926379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.